Insider Selling: Medpace (NASDAQ:MEDP) CEO Sells 14,747 Shares of Stock

Medpace Holdings, Inc. (NASDAQ:MEDP) CEO August Troendle sold 14,747 shares of the business’s stock in a transaction on Friday, November 14th. The shares were sold at an average price of $595.26, for a total transaction of $8,778,299.22. Following the transaction, the chief executive officer owned 899,415 shares in the company, valued at $535,385,772.90. This trade represents a 1.61% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Medpace Price Performance

Shares of MEDP traded up $4.42 during midday trading on Tuesday, hitting $590.18. The stock had a trading volume of 219,107 shares, compared to its average volume of 415,017. Medpace Holdings, Inc. has a 1 year low of $250.05 and a 1 year high of $625.00. The stock’s 50 day moving average is $541.26 and its 200 day moving average is $426.46. The firm has a market cap of $16.62 billion, a PE ratio of 41.27, a price-to-earnings-growth ratio of 2.67 and a beta of 1.42.

Medpace (NASDAQ:MEDP) last issued its quarterly earnings results on Wednesday, October 22nd. The company reported $3.86 EPS for the quarter, beating the consensus estimate of $3.50 by $0.36. The company had revenue of $659.90 million for the quarter, compared to the consensus estimate of $640.49 million. Medpace had a net margin of 18.36% and a return on equity of 91.88%. The firm’s revenue was up 23.7% compared to the same quarter last year. During the same period in the prior year, the firm posted $3.01 EPS. Medpace has set its FY 2025 guidance at 14.600-14.860 EPS. As a group, equities research analysts expect that Medpace Holdings, Inc. will post 12.29 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on MEDP shares. Wall Street Zen raised Medpace from a “hold” rating to a “buy” rating in a research note on Saturday, October 25th. UBS Group lowered Medpace from a “neutral” rating to a “sell” rating and increased their target price for the stock from $300.00 to $305.00 in a research note on Tuesday, July 29th. Jefferies Financial Group boosted their target price on shares of Medpace from $400.00 to $450.00 and gave the company a “hold” rating in a research note on Tuesday, September 9th. Zacks Research upgraded shares of Medpace from a “hold” rating to a “strong-buy” rating in a report on Monday, October 27th. Finally, Deutsche Bank Aktiengesellschaft raised their price target on shares of Medpace from $270.00 to $430.00 and gave the stock a “hold” rating in a research note on Wednesday, July 23rd. One research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, ten have assigned a Hold rating and four have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $487.18.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the business. Quent Capital LLC bought a new position in shares of Medpace during the third quarter valued at approximately $25,000. Optiver Holding B.V. purchased a new stake in Medpace during the third quarter worth $27,000. Geneos Wealth Management Inc. boosted its position in Medpace by 64.9% during the 1st quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock valued at $29,000 after acquiring an additional 37 shares in the last quarter. Brooklyn Investment Group increased its holdings in shares of Medpace by 244.8% in the 1st quarter. Brooklyn Investment Group now owns 100 shares of the company’s stock valued at $30,000 after acquiring an additional 71 shares during the period. Finally, Quarry LP bought a new position in shares of Medpace in the 3rd quarter worth $35,000. Hedge funds and other institutional investors own 77.98% of the company’s stock.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.